inherent in a study design already 1 year in length, might be considered a concern.
However, we were confi dent from our previous crossover studies that carry-over would not be a problem, and are supported by the sensitivity analyses, including the
absence of change in blood pressure during the placebo cycle, and similarity of the primary outcome result to the retrospective parallel group analysis of cycle 1 alone.